|Description||Devazepide is a potent and orally active cholecystokinin A(CCK-A) receptor antagonist with IC50 value of 0.26 nM. It is a derivative of benzodiazepine that displays appetite-stimulant effects. It blocks the anorectic response to CCK-8 and increases food intake in rats. It increases appetite and accelerates gastric emptying. It is used as a potential treatment for a variety of gastrointestinal problems including gastroparesis, dyspepsia and gastric reflux. It was developed by Merck Sharp & Dohme and was terminated in clinic phase 2 trials.|
|Solubility||Soluble to 100 mM in DMSO and to 50 mM in ethanol|
|Application||Devazepide is used as a potential treatment for a variety of gastrointestinal problems including gastroparesis, dyspepsia and gastric reflux.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||758.6±60.0 °C | Condition: Press: 760 Torr|
|Density||1.31±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||Devazepide was developed by Merck Sharp & Dohme and was terminated in clinic phase 2 trials.|
Devazepide is a potent and orally active cholecystokinin A(CCK-A) receptor antagonist with IC50 value of 0.26 nM. It is a derivative of benzodiazepine that disp...
Loxiglumide is an orally active, potent and selective small-molecule antagonist of the cholecystokinin receptor CCKA. It stimulates calorie intake and hunger fe...
LY 219057, a phenylpyrazolidine derivative, has been found to be a CCK receptor antagonist that could probably be useful in gastrointestinal disorder studies.
CE-326597 is a selective type 1 cholecystokinin receptor （CCK1R）agonist. In Mar 2009, Phase-II for Obesity in World was discontinued.